Citations

Clear

866 citation(s) found for "Shannon, J".

Design, implementation, and assessment of an independent second-check system for proton and carbon-ion pencil-beam scanning: delivery-aware Monte Carlo and microdosimetric RBE-weighted dose
Furutani, Keith, Hartzell, Shannon

Mayo Clinic

Frontiers in Oncology | October 20, 2026 | Volume: 16 | Issue: No issue available | Pages: No page available

10.3389/fonc.2026.1949825 | PMID 42978625 Get It

Background Independent second checks for proton and carbon-ion pencil-beam scanning should assess the planned physical dose, the expected delivery sequence, and the model-dependent relative biological effectiveness (RBE)-weighted dose. Objective The aim of this study was to design, implement, and assess a traceable second-check system that combines delivery-aware Monte Carlo transport with microdosimetric RBE calculation for both particle species. Methods The system receives Digital Imaging and Communications in Medicine (DICOM) planning data, converts the discrete spot sequence into a predicted delivery sequence for dose-driven continuous scanning (DDCS), generates weighted particle histories, and performs independent TOPAS/Geant4 transport. It scores physical dose, dose-averaged linear energy transfer (LETd), and voxel-level microdosimetric quantities. For both beam types, the scored lineal-energy distribution is represented using abridged microdosimetry distribution methodology (AMDM) and processed with the Mayo Clinic Florida microdosimetric kinetic model (MCF MKM). The proton branch additionally produces a fixed-RBE-weighted dose using RBE = 1.1. No fixed-RBE model is used for carbon ions. Proton assessment included component tests, single-energy source, transport, and scoring checks at 70.0, 170.2, and 229.1 MeV, patient-level evaluations using de-identified plans, and operational timing. Carbon-ion assessment used a pre-existing Monte Carlo dataset to evaluate component-level handling and visualization of AMDM descriptors, the MCF MKM RBE factor, and RBE-weighted dose. Results The integrated workflow completed plan receiving, delivery-sequence generation, particle transport, physical and biological dose calculation, comparison, and report generation. The proton case for which detailed quantitative end-to-end results were reported was classified as REVIEW REQUIRED because not all dosimetric comparison criteria were met. A pre-existing carbon-ion dataset was used to verify the component-level handling and separate presentation of physical dose, AMDM descriptors, RBE factor, and RBE-weighted dose. Predicted DDCS timing and the stationary-versus-moving irradiation components were not benchmarked against machine logs or measurements. Conclusion A common delivery-aware platform was implemented to support independent physical dose and microdosimetric RBE-weighted dose assessment for proton and carbon-ion treatments while retaining beam-specific dose conventions and biological model information. Further local commissioning and multicase validation are required before clinical use.
Leveraging Urinary Proteomics to Advance Pathophysiologic and Biomarker Perspectives of Chronic Kidney Disease in Cats
Brusach, Katelyn B , Shannon, Ariana E.

Mayo Clinic

Journal of Proteome Research | October 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1021/acs.jproteome.6c00357 | PMID 42992900 Get It

Abstract Chronic kidney disease (CKD) is one of the most prevalent diseases in feline medicine. Mass spectrometry-based urinary proteomics offers powerful insight into biomarker candidates and disease subtyping in CKD by measuring protein profiles rather than individual proteins. This study aims to measure the urinary proteome to identify protein profiles in cats with and without CKD to gain pathophysiological insights into the disease and more precisely diagnose CKD. Here, we identify 2,219 urinary proteins in the feline urinary proteome. Using univariate biomarker analysis, we show that MMP-7 may be a promising biomarker of CKD in cats. We then demonstrate the power of using protein profiles rather than individual proteins by grouping proteins based on how they trend across disease states. The changes to the global urinary proteomes of individual cats showed three distinct groups of CKD cats with unique protein profiles, suggesting that different pathophysiological mechanisms mediate disease subtypes. We demonstrate that large-scale urinary proteomics may provide a powerful framework for discovering candidate biomarkers that advance the subtyping and mechanistic understanding of feline CKD.
Hidradenitis Suppurativa: Part of a Tetrad of Follicular Occlusion Disorders
Sie, Shannon P., Sibbald, R. Gary, Akpala, Christeebella, Miller, Jonathan, Coutts, Patricia, Alavi, A., Walker, David , Akpala, Christeebella O.

Mayo Clinic

Advances in Skin & Wound Care | September 18, 2026 | Volume: 39 | Issue: 9 | Pages: 462-475

10.1097/asw.0000000000000523 | PMID 42759045 Get It

Follicular occlusion disorders (FOD) represent a tetrad of chronic, recurrent inflammatory conditions united by a common pathophysiologic mechanism: follicular hyperkeratosis leading to occlusion, rupture, and subsequent abscess or sinus tract formation. First conceptualized as a triad in the 1950s and later expanded to a tetrad in the 1970s, this grouping includes hidradenitis suppurativa (HS), acne conglobata (AC), dissecting cellulitis of the scalp (DCS), and pilonidal sinus (PS). Despite their shared pathogenesis, each condition carries distinct clinical features, epidemiological profiles, and management considerations. This article aims to provide a comprehensive review of FOD, with a primary emphasis on HS (the most prevalent of the disorders). Hidradenitis suppurativa is a debilitating disease affecting ∼1% of the global population, predominantly in females, and the diagnosis is often delayed by 7 or more years. Multiple genes are linked to FOD patients with a positive familial history in 35% to 40%, along with lifestyle factors (smoking, alcohol consumption, and obesity). Key inflammatory mediators, including TNF-α, IL-1β, and IL-17, drive the chronic tissue destruction characteristic of FOD, frequently resulting in scarring, lymphedema, and significant psychosocial impairment. Wound care is critical and often underemphasized in disease management. This article outlines evidence-informed wound care strategies for both nonsurgical and postsurgical presentations, including dressing selection, exudate and odor management, pain and itch control, infection management, and the emerging role of intravenous ertapenem as rescue therapy. An interprofessional approach, integrating dermatology, surgery, wound care nursing, and psychosocial support, is emphasized throughout as essential to improving patient outcomes and quality of life. GENERAL PURPOSE: To increase clinicians’ understanding of follicular occlusion disorders including the associated risk factors, clinical manifestations, and evidence-based approaches for management. TARGET AUDIENCE: This continuing education activity is intended for physicians, physician assistants, nurse practitioners, and registered nurses with an interest in skin and wound care. LEARNING OBJECTIVES/OUTCOMES: After participating in this educational activity, the participant will: Assess clinical characteristics of each follicular occlusion disorder Evaluate the basic disease mechanisms for follicular occlusion disorders Describe principal disease burdens that require wound care attention Identify the unique wound care strategies and follicular occlusion disorder challenges JOURNAL/aswca/04.03/00129334-202610000-00004/figure1/v/2026-09-18T181327Z/r/image-jpeg
Pulmonary Function Test Order Redesign: A Quality Improvement Initiative
Sujanyal, Saurabh, Omercikoglu, Elcin , Alazab, Heba, Griffin, Angie, Koirala, Tapendra , Burger, Charles, Beagle, Lisa, Atkins, Shannon, Helgeson, Scott A. , Helgeson, Scott A , Alazab, Heba

Mayo Clinic

Journal of Patient Safety | September 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/pts.0000000000001590 | PMID 42748326 Get It

Objectives: Pulmonary function tests (PFTs) are essential for diagnosis, management, and follow-up of a wide range of respiratory conditions as they provide quantitative insights into various aspects of lung function. Precision in ordering and scheduling PFTs, like any test, is crucial as errors can lead to misdiagnoses, delayed treatments, unnecessary retesting, inflated healthcare costs, and potentially compromised patient care. Hence, the aim of this quality improvement initiative was to reduce the PFT ordering error rate to below 5% by redesigning the ordering workflow and implementing a standardized order set tailored to specific clinical scenarios. Methods: The quality improvement initiative was implemented from August 2023 to March 2024. Data was collected from the electronic medical record (EMR) using predefined operational definitions to identify incorrect PFT orders and scheduling errors. A redesigned orderset was created to align with specific clinical presentations, including symptoms, suspected diagnosis, confirmed diagnosis, and presurgical evaluation. Scheduling was also restructured to match the expected testing time for each category. Education sessions were conducted with ordering providers, and ongoing feedback loops were established. Results: Among 575 preintervention PFT orders, 130 (22.6%) contained errors. Following implementation, review of 607 postintervention orders showed a reduction in error rates to 4.1%, representing an ∼80% improvement ( P <0.01). There was no increase in unnecessary testing, supporting the effectiveness of the intervention without unintended negative consequences. Conclusions: Implementation of a knowledge-based CDSS with standardized order sets significantly reduced PFT ordering errors and variability, improving guideline adherence and care quality. Continued refinement and integration with evolving technologies are essential for broader applicability.
Assessing the influence of microdosimetric formalism on calculations of relative biological effectiveness in carbon ion radiotherapy
Hartzell, Shannon , Furutani, Keith M. , Parisi, Alessio , Beltran, Chris , Beltran, Chris J , Parisi, Alessio , Furutani, Keith M , Sato, Tatsuhiko

Mayo Clinic

Precision Radiation Oncology | August 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/pro6.70087 Get It

Cold and Room-Temperature Platelets in Cardiac Surgery
Spinella, Philip C., Zantek, Nicole D., Nicolson, Susan C., Khanna, Ashish K., Boisen, Michael L., Williams, Tiffany M. , Monteleone, Matthew, Pavey, Warren, Smith, Bradford B., Ahmed, M. Iqbal, Jeng, Eric, Flynn, B S, Joshi, Ravi V. , Preuss, James , Goswami, Dheeraj, Lewis, Choy, Tint, Hlaing , Kwak, Jenny , Sodha, Neel, Simon, Eric R. , Van, Philbert Y., Greilich, Philip E. , Booth, Frank V. McL., Carter, Camille, Keegan, Anastazia , Cap, Andrew P., Matuk, James, McGlothlin, Anna, Berry, Nicholas , Lewis, Roger , Steiner, Marie E., Group, CHIPS Investigator, Hu, Paula, Hawkins, Jaleah, Jobes, David R. , Fadeyi, Emmanuel A. , Reynolds, Abigail M.A., Bell, Carter G., Gandhi, Manish J., Montonye, Beth, Serna-Gallegos, Derek, Sultan, Ibrahim, Kinney, Stephanie , Molony, Kathleen, Hensch, Lisa, Resheidat, Ashraf, Malivers, Martine, Hahn, Rebbecca, Viellez, Annette Le, Pepperell, Dominic , Lu, Qun, Downey, Frank, Haeger, Kayla N., Baltagi, Sirine , Jaquiss, Robert D.B., Noland, Daniel K., Cole, Regina, Duffin, Aspen, Scott, John P., Zeng, Long, Ballew, Angie, Webb, Christopher, Jessen, Michael, Hopson, Erryn, Mickle, Peri, Kavanagh, Simon, Matzelle, Shannon, Mennie, Colleen, Davenport, Robertson, Chlebeck, Therese, Zenk, Emmy, Lotz, Daniel T., Choi, Warren , Hobbs, Rhonda, Baptise, Amanda, DeChristopher, Phillip, Schoenecker, Nancy, Rodheim, Dianna, Connor, Joseph, Griese, Daniel J., McGuire, Erin, VanSandt, Mandy, Sera, Valerie, O’Donovan, Justine , Marks, Denese, Johnson, Lacey, Viele, Kert , Cholette, Jill M., Selke, Frank, Silverman, Toby, Shea, Susan, Yazer, Mark, Young, P. J., Ness, Paul Van, Dean, J. Michael, Shaz, Beth, Stubbs, James, Klompas, Allan M. , Spinella, Philip C. , Zantek, Nicole D. , VanBuren, John M. , Nicolson, Susan Craig , Khanna, Ashish K. , Boisen, Michael L , Monteleone, Matthew P., Bashir, Dalia A. , Pavey, Warren , Niebler, Robert A. , Jeng, Eric I-Hun , Goswami, Dheeraj , Yamada, Chisa , Lewis, Choy R., Cohn, Claudia S. , Sodha, Neel R. , Cap, Andrew , Matuk, James , Smith, Mark M. , Montonye, Beth L., Kaplan, Alesia , Kinney, Stephanie , Resheidat, Ashraf M., Downey, Francis X. , Ballew, Angie , Matzelle, Shannon A, Crowe, Liz , DeChristopher, Phillip J., Griese, Daniel, Sera, Valerie, Marks, Denese C. , Johnson, Lacey , Cholette, Jill M., Levy, Jerrold H. , Silverman, Toby , Yazer, Mark H. , Strandenes, Geir , Shaz, Beth H. , Stubbs, James R.

Mayo Clinic

JAMA | August 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jama.2026.13328 | PMID 42606886 Get It

Importance Patients undergoing cardiac surgery with cardiopulmonary bypass often require platelet transfusions for bleeding. Platelets are routinely stored at room temperature (20-24 °C) for up to 5 to 7 days; however, cold storage (1-6 °C) may allow for increased storage duration without loss of hemostatic function. Objective To determine the maximum cold-storage duration, up to 21 days, for which cold-stored platelets (CSPs) are noninferior or superior in hemostatic efficacy to room-temperature platelets (RTPs) when transfused in actively bleeding patients undergoing cardiac surgery with cardiopulmonary bypass. Design, Setting, and Participants A phase 3, multicenter, randomized, partially blinded, adaptive, noninferiority, storage duration–ranging trial conducted in pediatric and adult patients undergoing cardiac surgery with planned cardiopulmonary bypass at 27 sites in the US and Australia from December 2021 to March 2025. Statistical analysis was conducted from September 9 to October 3, 2025. Intervention Patients were randomized 2:1 to receive CSPs with a maximum of 21 days of storage vs RTPs with a maximum of 7 days of storage. Main Outcomes and Measures The primary outcome was a hemostatic efficacy score with values ranging from 1 to 5 and higher values indicating greater bleeding. The noninferiority margin was 1 point. The success criterion was met if at least 1 cold-storage duration of 7 days or more had a posterior probability of noninferiority of at least 97.5%. The secondary outcome was 24-hour chest tube output. Results Of the 1000 patients who underwent platelet transfusion, 989 were included in the primary analysis (650 CSPs and 339 RTPs). The cohort had a mean (SD) age of 42.1 (30.1) years and 67.8% were male. CSPs were noninferior to RTPs for the primary outcome, with a probability of greater than 99.9% for all cold-storage durations. Pooled across storage durations, CSPs had a mean difference from RTPs of 0.09 (95% credible interval, −0.06 to 0.23). Median (IQR) chest tube output at 24 hours (8.9 mL/kg [5.2-15.4] for CSPs vs 8.4 mL/kg [5.5-15.9] for RTPs; difference in medians, 0.4 [95% CI, −1.0 to 1.5]) was not statistically different between study groups. In a post hoc analysis, as all storage durations were noninferior, considering the CSPs as a single group, the hemostatic efficacy score was similar between both groups: mean (SD) of 3.08 (1.15) CSPs vs 2.99 (1.10) RTPs. There were no differences in venous or arterial thrombotic events, transfusion-associated adverse events, acute respiratory distress syndrome, kidney failure, septic shock, and mortality between the study groups, except for increased reexploration rates in the CSP group. Conclusions and Relevance For patients undergoing cardiac surgery, CSPs stored up to 21 days are noninferior to RTPs for the control of active surgical bleeding. Use of CSPs may allow for increased availability of platelets by reducing wastage and shortages and may allow for incorporation of platelets into inventory at locations where platelets cannot be maintained due to the 5- to 7-day shelf life of RTPs. Trial Registration ClinicalTrials.gov Identifier: NCT04834414
NCCN Guidelines® Insights: Survivorship, Version 3.2026
Peterson, L., McDonough, Allison L. , Ansbaugh, Shannon M., Heredia, Ella J. Ariza, Armenian, Saro, Baker, K. Scott, Cathcart-Rake, Elizabeth J., Cohen, Stuart H. , Fairman, Nathan, Feliciano, Josephine, Flores, Tessa , Gabel, Nicolette , Hill‐Kayser, Christine E. , Hock, Karen, Kline-Quiroz, Cristina, Lee, Nita K., Mooney, Kathi, Moryl, Natalie , Neuman, Heather, Overholser, Linda, Patel, Chirayu G. , Porpiglia, Andrea, Saidain, Ava, Schapira, Lidia , Smith, Sophia K., Tenner, Laura, Ah, Diane Von , Zee, Phyllis, Freedman-Cass, Deborah, McMillian, Nicole, Ariza‐Heredia, Ella , Armenian, Saro H. , Ballinger, Tarah Jean , Cathcart-Rake, Elizabeth , Day, Andrew T. , Evgeniou, Evgenios , Feliciano, Josephine , Friedman, Debra L. , Hock, Karen , Kline‐Quiroz, Cristina , Moore, Halle C. F. , Neuman, Heather B. , Overholser, Linda , Porpiglia, Andrea S., Rogers, Laura Q. , Yang, Eric H. , Freedman-Cass, Deborah A., McMillian, Nicole R.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 17, 2026 | Volume: 24 | Issue: 8 | Pages: No page available

10.6004/jnccn.2026.0039 | PMID 42607712 Get It

The NCCN Guidelines for Survivorship offer guidance for health care providers who care for survivors of adult-onset cancer. These guidelines include screening, evaluation, and treatment recommendations for common physical and psychosocial problems resulting from cancer and its treatment and provide a framework for care coordination. They also present guidance for helping cancer survivors to enhance their wellness and maintain a healthy lifestyle. This article summarizes the panel’s current recommendations and recent updates regarding anxiety, depression, distress, and trauma in cancer survivors.
Integrated coding-noncoding genome annotation expands single-cell transcriptomic discovery and identifies clinically relevant noncoding RNAs in multiple myeloma
Bakhtiari, Mojtaba , Henderson, Edward, Ferguson, Katherine , Pilcher, William C., Gonzalez-Kozlova, Edgar, Karagkouni, Dimitra, Matulis, Shannon M. , Acharya, Chaitanya R., Avigan, David, Vij, Ravi, Parekh, Samir, Ding, Li, Kumar, Shaji, Nooka, Ajay, Mulligan, George, Lonial, Sagar, Bhasin, Manoj, Michaud, Marina E. , Ohlstrom, Denis , Satpathy, Sarthak , Pilcher, William , Gonzalez‐Kozlova, Edgar , Karagkouni, Dimitra , Acharya, Chaitanya R. , Avigan, David , Vij, Ravi , Parekh, Samir , Cho, Hearn Jay , Vlachos, Ioannis S. , Kumar, Shaji , Gnjatic, Sacha , Nooka, Ajay K. , Lonial, Sagar , Boise, Lawrence , Bhasin, Manoj K

Mayo Clinic

No container title available | August 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.08.09.743753 Get It

Abstract Although the human genome encodes a vast repertoire of noncoding RNAs that regulate gene expression, the noncoding genome remains underexplored due to technical challenges. Specifically, during transcriptomic sequencing data alignment, the overlap between noncoding and coding loci can create ambiguous read alignments that are subsequently discarded from downstream analysis. For this reason, most of the noncoding genome is excluded from standard genomic annotations used for sequencing alignment. To address this challenge and enable concurrent profiling of the coding and noncoding transcriptome, we systematically integrated standard coding (GENCODE) and noncoding (LncBook) genome annotations, preserving coding gene annotations and removing overlapping noncoding regions. The resulting integrated genome annotation expanded the number of annotated noncoding genes from 40,785 to 138,296 while preserving all coding genes and reducing ambiguous read assignment. To evaluate the utility of our integrated genome annotation for uncovering novel, biologically relevant noncoding RNAs (ncRNAs), we realigned CD138-positive bulk RNA-seq (N = 942) and CD138-negative single-cell RNA-seq (N = 478) data from the MMRF CoMMpass study, generating a comprehensive coding-noncoding atlas of the myeloma bone marrow microenvironment with noncoding genes representing 51% of highly variable genes and displaying significant cell type specificity. Tumor expression profiling based on this integrated profiling identified 15 clusters, including two enriched for amp(1q21) or t(4;14) and associated with shorter progression-free survival (PFS). Differential expression and systematic filtering yielded 19 candidate high-risk ncRNAs, including previously uncharacterized ENSG00000310209 , which was associated with poor PFS (HR = 1.141, P = 0.0025), increased IRF4 activity, Wnt pathway activation, CCL5 signaling, and the accumulation of anergic-like CD8+ T cells. These findings establish integrated coding-noncoding analysis as a strategic approach for discovering functional ncRNAs from transcriptomic sequencing data.
TLSB-18 CLINICAL UTILITY OF CEREBROSPINAL FLUID CIRCULATING TUMOR DNA ASSAY IN PATIENTS WITH SUSPECTED LEPTOMENINGEAL DISEASE: A REAL-WORLD DESCRIPTIVE ANALYSIS
Mrugala, Maciej, Bendok, Bernard, Alyx, Porter, Texidor, Rhonda, Thompson, Tracy, Vora, Sujay, Ensign, Shannon Fortin, Vora, Sujay A., Ensign, Shannon P. Fortin

Mayo Clinic

Neuro-Oncology Advances | August 7, 2026 | Volume: 8 | Issue: Supplement_6 | Pages: No page available

10.1093/noajnl/vdag161.136 Get It

Abstract Background Leptomeningeal disease (LMD) remains a challenging complication of both solid tumors and hematologic malignancies, with diagnosis traditionally relying on cerebrospinal fluid (CSF) cytology, which has limited sensitivity. Circulating tumor DNA (ctDNA) analysis in CSF has emerged as a promising diagnostic and molecular profiling tool that may improve detection and guide treatment decisions. We will report real-world clinical experience using a CSF ctDNA assay (Menarini Silicon Biosystems) in routine neuro-oncology practice. Methods Retrospective analysis of over 100 CSF specimens obtained from patients with suspected or confirmed LMD will be conducted. Clinical data to be collected: patient demographics, tumor histology, indication for testing, and prior treatments. ctDNA assay results will be compared with conventional CSF cytology. Molecular alterations identified through ctDNA testing will be recorded, along with subsequent treatment decisions, including use of targeted therapies, systemic therapy modifications, radiation therapy, or intrathecal approaches. Preliminary clinical outcomes, including radiographic response, progression patterns, and survival trends, will be explored. Descriptive statistical methods will be used to summarize the findings. Results We anticipate that among analyzed specimens, ctDNA testing will provide clinically meaningful diagnostic yield across multiple tumor histologies. Concordance and discordance patterns between ctDNA results and conventional cytology will be evaluated, including cases in which ctDNA identified molecular alterations despite negative cytology. Actionable genomic findings in a subset of patients will be analyzed and presented. Early outcome observations that ctDNA-informed management may facilitate more personalized care will be reported. Conclusions CSF ctDNA analysis represents a feasible and informative adjunct to conventional cytology in the evaluation of patients with suspected LMD in real-world clinical practice. Beyond diagnostic support, molecular profiling from ctDNA may influence treatment selection and enable precision oncology approaches in this high-risk population. Prospective studies are warranted to define sensitivity, specificity, and the impact of ctDNA-guided interventions on clinical outcomes.
TNK1 is a targetable JAK-independent driver of STAT signaling and inflammation
Scott, Samuel, Vaughan, Alec , Egbert, Christina M., Chan, Tsz‐Yin, Bustos, Yaphet , Ashworth, Spencer, Truman, Jacob M., Moreno, Angela Per, Tsang, Tsz‐Ming, Jayatunge, Dasun N., Yang, Jingshu, Nelson, Paige, Al-Sudani, Fatima, Tarara, Madelyn, Kohler, Emmalee, Mendiola, Nelson E. Pereira, Soderblom, Erik J. , Kolasangiani, Reza , Dobish, Kasidy K., Knobel, Beate, Buckley, Shannon M., Bidone, Tamara C., Morawe, Mareen , Armacki, Milena , Andersen, Joshua L., Stewart, Paul A , Smoot, Rory L , López-Palacios, Tania P. , Madhusanka, Deshan , Scott, Samuel M., Egbert, Christina M. , Truman, Jacob, Jayatunge, Dasun , Nelson, Paige, Stubben, Chris , Buckley, Shannon M. , Bidone, Tamara C. , Smoot, Rory L. , Uchida, Amiko M. , Andersen, Joshua L.

Mayo Clinic

Genes & Development | August 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/gad.353368.125 | PMID 42547268 Get It

Deregulated inflammatory signaling via STAT family transcription factors, particularly STAT1, underlies a variety of immune-related diseases, including inflammatory bowel disease. Whereas activation of STATs by JAKs via canonical receptor-driven JAK–STAT signaling is well understood, little is known about JAK-independent mechanisms of STAT activation. Here, we identify the understudied nonreceptor tyrosine kinase TNK1 as a therapeutically targetable, JAK-independent activator of STAT signaling. Using a multiomics approach, we mapped a network of TNK1 substrates associated with protein condensates and proinflammatory signaling, including STAT1. We found that TNK1, but not its sister kinase ACK1, directly phosphorylates STATs at well described STAT-activating JAK sites. In cells, TNK1-mediated STAT1 phosphorylation and activation occurs independently of JAKs. Imaging and interactomics data suggest that TNK1 interacts with STAT1 in cytosolic condensates, which likely compartmentalize TNK1-substrate interactions. We show that an intrinsically disordered proline-rich region in TNK1, which includes a 14-3-3 docking phosphorylation site, is required for the formation of kinase-active TNK1 condensates and STAT1 phosphorylation. Mutations within the proline-rich region that eliminate 14-3-3 binding increase formation of TNK1 condensates, suggesting a model in which 14-3-3 acts as a clamp that constrains the flexible PRR to inhibit condensate formation and STAT1 activation. Finally, we show that TNK1 is a targetable driver of STAT1-mediated inflammation in the gut as inhibition of TNK1 reduces active STAT1 in the colon and ameliorates colitis symptoms in mice.